Allogene Therapeutics Inc.
Organization details
- Legal name
- Allogene Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Headquarters city
- South SAN Francisco
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- ALLO
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001737287
- EIN
- 82-3562771
Board of directors
-
Arie Belldegrun · DirectorSince 2023
-
David D. Chang · Director · President and CEOSince 2023
-
Deborah M. Messemer · DirectorSince 2023
-
Elizabeth A. Barrett · DirectorSince 2023
-
Franz B. Humer · DirectorSince 2023
-
Joshua A. Kazam · DirectorSince 2023
-
Owen N. Witte · DirectorSince 2023
-
Stephen Mayo · DirectorSince 2023
-
Vicki L. Sato · DirectorSince 2023
Chief executives
Director election results
Annual meeting of June 18, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
82.9%
-
88.6%
-
88.6%
Board connections
4 of this board's directors also sit on 8 other boards. 6 are in the same sector.
-
Denali Therapeutics Inc. Same sectorvia Vicki L. Sato
-
Ginkgo Bioworks Holdings Inc. Same sectorvia Arie Belldegrun
-
Merck & Company Inc. Same sectorvia Stephen Mayo
- via Deborah M. Messemer
-
Sarepta Therapeutics Inc. Same sectorvia Stephen Mayo
- via Deborah M. Messemer
-
UroGen Pharma Ltd. Same sectorvia Arie Belldegrun
-
Vir Biotechnology Inc. Same sectorvia Vicki L. Sato
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $668,812
- 15 sales by 6 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 21, 2026 | Geoffrey M. Parker Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | −36,342 | $1.34 | $48,698 |
| Aug 21, 2026 | Douglas Earl Martin Officer (SVP, General Counsel) | Open-market sale | −29,697 | $2.12 | $62,958 |
| Jun 18, 2026 | Joshua A. Kazam Director | Option exercise | +47,700 | — | — |
| Apr 21, 2026 | Yoshiyama Annie Officer (SVP, Finance) | Open-market sale | −9,586 | $2.31 | $22,144 |
| Mar 31, 2026 | Beneski Benjamin Machinas Officer (SVP, Chief Technical Officer) | Open-market sale | −2,867 | $2.50 | $7,168 |
| Mar 16, 2026 | Beneski Benjamin Machinas Officer (SVP, Chief Technical Officer) | Open-market sale | −4,835 | $2.47 | $11,942 |
| Mar 16, 2026 | David D. Chang Director, Officer (President and CEO) | Open-market sale | −47,763 | $2.47 | $117,975 |
| Mar 2, 2026 | Beneski Benjamin Machinas Officer (SVP, Chief Technical Officer) | Open-market sale | −7,132 | $2.60 | $18,543 |
| Feb 2, 2026 | Beneski Benjamin Machinas Officer (SVP, Chief Technical Officer) | Open-market sale | −7,549 | $1.73 | $13,060 |
| Feb 2, 2026 | David D. Chang Director, Officer (President and CEO) | Open-market sale | −95,269 | $1.80 | $171,484 |
| Feb 2, 2026 | Geoffrey M. Parker Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | −24,001 | $1.76 | $42,242 |
| Feb 2, 2026 | Douglas Earl Martin Officer (SVP, General Counsel) | Open-market sale | −22,900 | $1.76 | $40,304 |
| Feb 2, 2026 | Yoshiyama Annie Officer (SVP, Finance) | Open-market sale | −4,167 | $1.72 | $7,167 |
| Feb 2, 2026 | Roberts Zachary Officer (EVP of R&D) | Open-market sale | −35,700 | $1.77 | $63,189 |
| Jan 21, 2026 | Roberts Zachary Officer (EVP of R&D) | Open-market sale | −26,269 | $1.56 | $40,980 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Allogene Therapeutics Inc.
Who is the CEO of Allogene Therapeutics Inc.?
David D. Chang is Allogene Therapeutics Inc.'s President and CEO.
How many directors are on Allogene Therapeutics Inc.'s board?
Allogene Therapeutics Inc.'s board has 9 directors: Arie Belldegrun, David D. Chang, Deborah M. Messemer, Elizabeth A. Barrett, Franz B. Humer, Joshua A. Kazam, Owen N. Witte, Stephen Mayo and Vicki L. Sato.
Are Allogene Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Allogene Therapeutics Inc. insiders made no open-market purchases and sold $668,812 of shares in 15 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="allogene-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.